BridgeBio Pharma (BBIO) Net Equity Issued and Repurchased (2018 - 2024)

BridgeBio Pharma has reported Net Equity Issued and Repurchased for 4 years, with the latest figure at -$18000.0 in Q3 2024.

• Quarterly Net Equity Issued and Repurchased fell 100.01% year-over-year to -$18000.0 in Q3 2024, while the trailing twelve-month figure through Jun 2025 was -$18000.0 (down 100.0% YoY) and the FY2024 annual result came in at $314.7 million, down 30.03% from the prior year.
• Net Equity Issued and Repurchased declined to -$18000.0 in Q3 2024 per BBIO's latest filing, from $38.2 million in the prior quarter.
• Over five years, Net Equity Issued and Repurchased peaked at $315.3 million in Q1 2024 and troughed at -$454000.0 in Q4 2023.
• A 3-year average of $92.9 million and a median of $21.5 million in 2022 frame the typical range for Net Equity Issued and Repurchased.
• The sharpest annual moves came in 2023 and 2024: Net Equity Issued and Repurchased plunged 109.27% in 2023, then soared 3594.0% in 2024.
• Over 3 years, Net Equity Issued and Repurchased stood at $4.9 million in 2022, then slumped by 109.27% to -$454000.0 in 2023, then soared by 96.04% to -$18000.0 in 2024.
• According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered -$18000.0, $38.2 million, and $315.3 million for Q3 2024, Q2 2024, and Q1 2024 respectively.